Functional selectivity through protean and biased agonism: who steers the ship?
- PMID: 17901198
- DOI: 10.1124/mol.107.040352
Functional selectivity through protean and biased agonism: who steers the ship?
Abstract
This article describes functional selectivity of agonists and antagonists and distinguishes conventional cell-based functional selectivity, where the strength of signal produces selective signaling in various organs, from true receptor active-state based selectivity, also alternatively referred to in the literature as "stimulus trafficking," "biased agonism," and "collateral efficacy." This latter mechanism of selectivity depends on the ligand-related conformation of the receptor and is not compatible with the parsimonious view that agonists produce a single receptor active state. In addition, protean agonism is described, whereby a ligand produces positive agonism in quiescent systems and inverse agonism in constitutively active systems. This is a special case of active state-based selectivity in which the ligand produces an active state that is of lower efficacy than the natural constitutively active state. It is postulated that receptor active-state based selectivity, unlike cell-based functional selectivity, is controllable through the chemical structure of the ligand and is therefore more likely to be a viable avenue for therapeutic selectivity in the clinic. Reasons are given for differentiating receptor active-state based selectivity from conventional functional organ selectivity.
Similar articles
-
The evasive nature of drug efficacy: implications for drug discovery.Trends Pharmacol Sci. 2007 Aug;28(8):423-30. doi: 10.1016/j.tips.2007.06.005. Epub 2007 Jul 19. Trends Pharmacol Sci. 2007. PMID: 17659355 Review.
-
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.Trends Pharmacol Sci. 2007 Aug;28(8):407-15. doi: 10.1016/j.tips.2007.06.009. Epub 2007 Jul 13. Trends Pharmacol Sci. 2007. PMID: 17629960 Review.
-
Efficacy as a vector: the relative prevalence and paucity of inverse agonism.Mol Pharmacol. 2004 Jan;65(1):2-11. doi: 10.1124/mol.65.1.2. Mol Pharmacol. 2004. PMID: 14722230 Review.
-
The role of conformational ensembles of seven transmembrane receptors in functional selectivity.Curr Opin Pharmacol. 2010 Dec;10(6):775-81. doi: 10.1016/j.coph.2010.09.004. Curr Opin Pharmacol. 2010. PMID: 20933468 Review.
-
Molecular basis of inverse agonism in a G protein-coupled receptor.Nat Chem Biol. 2005 Jun;1(1):25-8. doi: 10.1038/nchembio705. Epub 2005 May 24. Nat Chem Biol. 2005. PMID: 16407989
Cited by
-
Opportunities for functional selectivity in GPCR antibodies.Biochem Pharmacol. 2013 Jan 15;85(2):147-52. doi: 10.1016/j.bcp.2012.08.021. Epub 2012 Sep 10. Biochem Pharmacol. 2013. PMID: 22975405 Free PMC article. Review.
-
Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.ACS Chem Neurosci. 2015 Apr 15;6(4):681-92. doi: 10.1021/acschemneuro.5b00020. Epub 2015 Feb 20. ACS Chem Neurosci. 2015. PMID: 25660762 Free PMC article.
-
Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9.Sci Signal. 2018 Sep 25;11(549):eaat7650. doi: 10.1126/scisignal.aat7650. Sci Signal. 2018. PMID: 30254056 Free PMC article.
-
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor.J Biol Chem. 2010 Oct 29;285(44):33949-58. doi: 10.1074/jbc.M110.138073. Epub 2010 Aug 17. J Biol Chem. 2010. PMID: 20716524 Free PMC article.
-
β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic _targets for Complex Age-Related Disorders.Front Pharmacol. 2018 Nov 28;9:1369. doi: 10.3389/fphar.2018.01369. eCollection 2018. Front Pharmacol. 2018. PMID: 30546309 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
